Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses hair loss treatments, specifically mentioning Spiro, Min, Fin, and RU. It highlights that Spiro is generally for women and can affect men's hormonal balance.

OP experienced side effects from finasteride and is considering using RU58841 to prevent hair loss during a testosterone cycle. They have also used minoxidil, Nizoral, alfatradiol, and fluridil successfully.

A user humorously suggests an extreme hair loss treatment regimen involving multiple medications and therapies, including Dutasteride, Minoxidil, RU58841, and others, claiming it would prevent hair loss but with potential side effects like gynecomastia. The conversation highlights concerns about safety, side effects, and the effectiveness of such a comprehensive approach.

A user is considering using RU58841 for female pattern baldness and is also planning to use Minoxidil. They are hesitant to ask their doctor for spironolactone due to its cosmetic nature and are experiencing significant hair loss possibly due to stress and hormonal issues.

A non-binary individual experienced hair loss after stopping hormone replacement therapy and is using oral Dutasteride, oral Minoxidil, and ketoconazole shampoo. They are hopeful for regrowth but may use wigs due to the high cost and uncertain effectiveness of additional treatments like mesotherapy and PRP.

The user reported healthier, firmer, and thicker hair follicles with minimal regrowth at the front after using Regenera Activa, topical finasteride, minoxidil, tretinoin, caffeine solution, and vitamin D supplements. Hair loss has stabilized with no side effects.

The conversation is about finding sources for topical anti-androgens like CB, pyrilutamide, fluridil, and aflatridol for hair loss treatment. The user is considering using CB powder from IndiaMart but is concerned about side effects from finasteride and minoxidil.

The conversation discusses the effectiveness of RU58841 for hair loss compared to pyrilutamide, which failed to show significant hair regrowth in trials. Some users report personal side effects with RU58841 and question the criteria for success in hair loss treatments.

The user transitioned from finasteride to Cyproterone and started using Minoxidil, resulting in healthier hair and regrowth. They plan to wean off Minoxidil in a year, depending on regrowth.

PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.

RU58841 and Pyrilutamide (Kx-826) are both topical anti-androgens, but neither is effective for hair regrowth. RU58841 has more anecdotal support, while Pyrilutamide has progressed further in trials, though both have limitations.

A 23-year-old male shares his positive progress using 0.5mg finasteride for hair loss, noting initial side effects like sore nipples that resolved after adjusting the dosage. Other users discuss their experiences with finasteride, including effects on libido and the trade-offs of using the medication.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

The user experienced a significant drop in libido and erectile issues after increasing their finasteride dosage, combining oral and topical treatments. They plan to take a break and resume using a lower concentration of topical finasteride to manage side effects.

A 33-year-old man shares his positive hair regrowth results using 1mg finasteride daily, 5% topical minoxidil twice daily, and a 0.5mm dermaroller weekly. He feels more confident and encourages others to try the routine despite potential side effects.

A 32-year-old male used 1.25mg oral finasteride daily and 1ml topical minoxidil twice daily for 24 weeks, experiencing improved skin and hair growth with initial side effects that resolved after three weeks. He plans to try dermastamping to address a stubborn cowlick area.

The conversation discusses skepticism about group buys for hair loss treatments, highlighting issues with unverified chemicals and the risks involved. It suggests stabilizing with dutasteride and minoxidil, and considering a hair transplant instead of experimenting with untested products.

The conversation discusses the effectiveness of different doses of finasteride for hair loss, questioning the need for 1mg daily when 0.5mg every other day has a similar impact on scalp DHT. A humorous reply suggests exaggerated side effects.

User reported initial hair regrowth with 0.25 mg finasteride taken four times a week, experiencing a second shedding phase, and no side effects. They also mentioned using RU58841 without success and plan to stop after a year.

Plant-based exosomes for hair loss lack scientific evidence and are considered high-risk with low evidence. Combining PRF with minoxidil and finasteride is suggested as a better option.

Finasteride may have positive effects by keeping testosterone levels higher, potentially maintaining youthfulness and physical performance as one ages. It could also help with conditions related to aging like andropause and sarcopenia without increasing estradiol levels.

The user is considering starting pyrilutamide before a scheduled hair transplant, having previously used oral minoxidil and finasteride with worsening results. They also tried dutasteride, which worsened their hair and made their skin oily.

Hair loss treatments RU55841, CB-03-01, and Eucapil were discussed, with concerns about needing increased dosages over time and potential side effects. A user suggested that CB's results could be due to various factors and that combining it with finasteride might slow down any upregulation.

The conversation is about choosing between RU58841 and topical spironolactone for hair loss treatment. The user is currently using a topical solution with minoxidil, alfatradiol, and progesterone, and is concerned about side effects and effectiveness of both RU58841 and spironolactone.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

A female experiencing hair loss while on testosterone replacement therapy is using oral Minoxidil, Spironolactone, and finasteride, but still losing hair. Suggestions include switching to dutasteride, using topical anti-androgens, and reducing Nizoral shampoo use to prevent scalp dryness.

The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.

KY-19382, an indirubin derivative, is discussed for its potential to stimulate hair growth and create new hair follicles. The conversation seeks experiences with synthesizing, topically applying, or orally administering KY-19382.

The conversation discusses hair loss treatments, specifically RU58841, with mentions of side effects from finasteride and dutasteride. Alternatives like Pyri, KX-826, and Breezula are also mentioned.

Peppermint Essential Oil (PEO) was discussed for its hair regrowth effects on shaved mice after 4 weeks. Specific treatments mentioned include Minoxidil (Min), Finasteride (Fin), and RU58841 (RU).